HK1157772A1 - - Google Patents

Info

Publication number
HK1157772A1
HK1157772A1 HK11112211A HK11112211A HK1157772A1 HK 1157772 A1 HK1157772 A1 HK 1157772A1 HK 11112211 A HK11112211 A HK 11112211A HK 11112211 A HK11112211 A HK 11112211A HK 1157772 A1 HK1157772 A1 HK 1157772A1
Authority
HK
Hong Kong
Application number
HK11112211A
Inventor
Roger Shen-Chu Chen
George W Muller
Markian S Jaworsky
Manohar T Saindane
Louise M Cameron
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US49972303P priority Critical
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1157772(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of HK1157772A1 publication Critical patent/HK1157772A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00Closures not otherwise provided for
    • B65D51/24Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/2807Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
    • B65D51/2857Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it
    • B65D51/2864Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it the element being a plug or like element closing a passage between the auxiliary container and the main container
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
HK11112211A 2003-09-04 2011-11-11 HK1157772A1 (xx)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US49972303P true 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
HK1157772A1 true HK1157772A1 (xx) 2014-04-17

Family

ID=34272860

Family Applications (6)

Application Number Title Priority Date Filing Date
HK06114094A HK1092388A1 (xx) 2003-09-04 2006-12-22
HK11102298A HK1148274A1 (xx) 2003-09-04 2011-03-08
HK11103233A HK1148974A1 (xx) 2003-09-04 2011-03-30
HK11112211A HK1157772A1 (xx) 2003-09-04 2011-11-11
HK12108343A HK1167646A1 (xx) 2003-09-04 2012-08-27
HK15102919.7A HK1202531A1 (en) 2003-09-04 2015-03-23 Hydrates of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine- 2,6-dione 3-(4--1--13 --2-)--2,6-

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK06114094A HK1092388A1 (xx) 2003-09-04 2006-12-22
HK11102298A HK1148274A1 (xx) 2003-09-04 2011-03-08
HK11103233A HK1148974A1 (xx) 2003-09-04 2011-03-30

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK12108343A HK1167646A1 (xx) 2003-09-04 2012-08-27
HK15102919.7A HK1202531A1 (en) 2003-09-04 2015-03-23 Hydrates of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine- 2,6-dione 3-(4--1--13 --2-)--2,6-

Country Status (36)

Country Link
US (18) US7465800B2 (xx)
EP (7) EP3045176B8 (xx)
JP (6) JP4733037B2 (xx)
KR (3) KR100979869B1 (xx)
CN (7) CN102675281B (xx)
AP (1) AP2324A (xx)
AR (2) AR047994A1 (xx)
AT (1) AT531369T (xx)
AU (2) AU2004270211B2 (xx)
BR (1) BRPI0414084A (xx)
CA (9) CA2688709C (xx)
CR (2) CR8291A (xx)
CY (1) CY1112017T1 (xx)
DK (5) DK3045176T3 (xx)
EA (1) EA009922B1 (xx)
EC (1) ECSP066467A (xx)
ES (5) ES2402808T3 (xx)
HK (6) HK1092388A1 (xx)
HR (1) HRP20110836T1 (xx)
HU (3) HUE041265T2 (xx)
IL (5) IL174067A (xx)
IS (1) IS8340A (xx)
MA (1) MA28084A1 (xx)
ME (3) ME01571B (xx)
MX (6) MX346261B (xx)
NO (4) NO336898B1 (xx)
NZ (1) NZ546054A (xx)
OA (1) OA13250A (xx)
PE (1) PE02842006A1 (xx)
PL (3) PL3045175T3 (xx)
PT (2) PT1667682E (xx)
RS (3) RS53104B (xx)
SI (2) SI2426118T1 (xx)
UA (1) UA83504C2 (xx)
WO (1) WO2005023192A2 (xx)
ZA (1) ZA200601858B (xx)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja) * 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション 4−アミノ−サリドマイドエナンチオマーの合成法
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP3045176B8 (en) * 2003-09-04 2018-12-12 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20050239842A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
CN101252957A (zh) * 2005-06-30 2008-08-27 人类起源公司 使用胎盘源胶原生物纤维的鼓膜修复
NZ565309A (en) 2005-06-30 2011-03-31 Celgene Corp Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US20070021762A1 (en) * 2005-07-13 2007-01-25 Qing Liu Ocular plug formed from placenta derived collagen biofabric
WO2007009062A2 (en) * 2005-07-13 2007-01-18 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US20080131522A1 (en) * 2006-10-03 2008-06-05 Qing Liu Use of placental biomaterial for ocular surgery
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
CN104623643A (zh) 2006-10-06 2015-05-20 人类起源公司 天然(端肽)胎盘胶原组合物
KR101955140B1 (ko) 2007-09-28 2019-03-06 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
WO2009085234A2 (en) * 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
KR20100124710A (ko) * 2008-03-11 2010-11-29 닥터 레디스 래보러토리즈, 인코포레이티드 레날리도미드의 제조
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
CN102272118A (zh) * 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 来那度胺的晶型及其制备方法
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
WO2010054833A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Intermediate und orale darreichungsformen enthaltend lenalidomid
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
AU2009314512B2 (en) * 2008-11-17 2013-04-04 Dr. Reddy's Laboratories Ltd. Lenalidomide solvates and processes
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
DK2403845T3 (da) 2009-03-02 2014-08-04 Generics Uk Ltd Forbedret proces.
WO2010129636A2 (en) * 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lenalidomide polymorph
WO2010135396A2 (en) 2009-05-19 2010-11-25 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
CN101665484B (zh) 2009-07-20 2012-11-21 上海皓元生物医药科技有限公司 一种制备来那度胺的方法
MX2012001890A (es) 2009-08-12 2012-03-26 Synthon Bv Sales de lenalidomida.
EP2477973B1 (en) 2009-09-16 2014-08-27 Ranbaxy Laboratories Limited Process for the preparation of a crystalline form of lenalidomide
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN101696205B (zh) * 2009-11-02 2011-10-19 严荣 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102060842B (zh) * 2009-11-02 2013-05-08 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of form b of lenalidomide
WO2011069608A1 (en) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体Ⅳ及其药用组合物
EP3106460B1 (en) 2010-02-11 2019-04-10 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8877932B2 (en) 2010-03-08 2014-11-04 Natco Pharma Limited Anhydrous lenalidomide form-I
ES2664872T3 (es) 2010-06-18 2018-04-23 Taiho Pharmaceutical Co., Ltd Moduladores PRPK-TPRKB y sus usos
WO2012047878A2 (en) 2010-10-04 2012-04-12 Lazo, Inc. Interactive advertisement environment
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
CN102643266B (zh) * 2011-02-17 2015-02-18 江苏先声药物研究有限公司 一种雷利度胺b晶型的制备方法
CN102070606A (zh) * 2011-02-17 2011-05-25 江苏先声药物研究有限公司 一种雷利度胺a晶型新的制备方法
RU2611007C2 (ru) 2011-03-11 2017-02-17 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
WO2012127493A1 (en) 2011-03-23 2012-09-27 Hetero Research Foundation Polymorphs of lenalidomide
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
CN104072476B (zh) * 2013-03-27 2018-08-21 江苏豪森药业集团有限公司 泊马度胺晶型及其制备方法和用途
WO2014170909A2 (en) * 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
SG10201705231PA (en) * 2013-09-03 2017-07-28 Fugro Chance Inc Interactive remote guidance system for seaborne vessels
EP2875817A1 (en) * 2013-11-26 2015-05-27 Synhton B.V. Pharmaceutical formulation comprising amorphous lenalidomide
WO2015116802A1 (en) 2014-01-29 2015-08-06 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
WO2015113314A1 (zh) * 2014-01-30 2015-08-06 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
CN104016966A (zh) * 2014-01-30 2014-09-03 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
JP2017513895A (ja) * 2014-04-22 2017-06-01 大塚製薬株式会社 ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途
CN105085473B (zh) * 2014-04-24 2019-06-18 江苏豪森药业集团有限公司 来那度胺晶型及其制备方法和医药用途
US20170107193A1 (en) * 2014-04-26 2017-04-20 Shilpa Medicare Limited Crystalline lenalidomide process
US20150348512A1 (en) * 2014-06-01 2015-12-03 Apple Inc. Method and apparatus for representing a device's traversal along a route
US10392364B2 (en) 2014-08-11 2019-08-27 Avra Laboratories Pvt. Ltd. Process for synthesis of lenalidomide
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
CN104610210B (zh) * 2015-02-05 2017-06-16 天津大学 一种脱氢醋酸钠无水物制备方法
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3135275A1 (en) 2015-08-27 2017-03-01 Grindeks, A Joint Stock Company Pharmaceutical composition capable of the incorporation of lenalidomide in various crystalline modifications
WO2017109041A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
RU2616976C1 (ru) * 2016-04-07 2017-04-19 Олег Ростиславович Михайлов Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
TW201811765A (zh) * 2016-08-25 2018-04-01 大陸商浙江海正藥業股份有限公司 來那度胺的晶型及其製備方法和用途
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
CN107400115A (zh) * 2017-08-04 2017-11-28 正大天晴药业集团股份有限公司 一种来那度胺的新结晶及其药物组合物
WO2019053612A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
WO2019081749A1 (en) 2017-10-26 2019-05-02 Synbias Pharma Ag Lenalidomide immediate release formulations
EP3505158A1 (en) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPH0331437B2 (xx) 1985-08-23 1991-05-07 Kirin Amgen Inc
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ES2163530T3 (es) * 1994-11-04 2002-02-01 Polymun Scient Immunbio Forsch Aplicacion de superoxido dismutasa (sod) en liposomas.
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
DE19601303A1 (de) 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
KR20050032629A (ko) 1996-07-24 2005-04-07 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-프탈이미드와 치환된2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린과 TNFα농도를 감소시키는 방법
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE69720735T9 (de) * 1996-08-12 2005-08-25 Celgene Corp. Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
DK0963200T3 (da) 1996-11-05 2005-10-24 Childrens Medical Center Præparater til inhibering af angiogenese omfattende thalidomid og et NSAID
AU5875598A (en) 1997-02-05 1998-08-26 University Of Hertfordshire Preparation of spheroids and their use in medicin or diagnosis
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200002681T2 (tr) * 1998-03-16 2000-12-21 Celgene Corporation 2-(2,6-Dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
NZ513953A (en) * 1999-03-18 2001-09-28 Celgene Corp Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CA2319872C (en) 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
WO2001070275A2 (en) 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
EP1272189A4 (en) 2000-03-31 2004-01-14 Celgene Corp Inhibition of cyclooxygenase-2 activity
DK1307197T3 (da) 2000-05-15 2006-07-03 Celgene Corp Sammensætninger til behandling af cancer indeholdende en topoisomeraseinhibitor og thalidomid
AU9123201A (en) * 2000-09-26 2002-04-08 Reddy S Res Foundation Novel polymorphic forms of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione maleate and process for their preparation
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja) 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション 4−アミノ−サリドマイドエナンチオマーの合成法
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
ES2325916T3 (es) 2001-08-06 2009-09-24 Entremed, Inc. Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
EP1496878A4 (en) 2002-04-12 2007-12-26 Celgene Corp Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CN102429908A (zh) 2002-05-17 2012-05-02 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2004001004A1 (es) 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
EP3045176B8 (en) 2003-09-04 2018-12-12 Celgene Corporation Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione
AT516288T (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
CA2579291C (en) 2004-09-03 2011-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
US20080064876A1 (en) 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
US20090092343A1 (en) * 2007-10-05 2009-04-09 Mary Thomson Locking Bag with Locking Handle
KR20100124710A (ko) * 2008-03-11 2010-11-29 닥터 레디스 래보러토리즈, 인코포레이티드 레날리도미드의 제조
CN101531653B (zh) 2008-03-13 2014-07-09 峡江和美药业有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
WO2010019435A2 (en) 2008-08-14 2010-02-18 Teva Pharmaceutical Industries Ltd. Solid states of atorvastatin potassium
CN102272118A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 来那度胺的晶型及其制备方法
WO2010054833A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Intermediate und orale darreichungsformen enthaltend lenalidomid
AU2009314512B2 (en) 2008-11-17 2013-04-04 Dr. Reddy's Laboratories Ltd. Lenalidomide solvates and processes
DK2403845T3 (da) 2009-03-02 2014-08-04 Generics Uk Ltd Forbedret proces.
WO2010129636A2 (en) 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lenalidomide polymorph
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司;严荣 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
MX2012001890A (es) 2009-08-12 2012-03-26 Synthon Bv Sales de lenalidomida.
CA2773012A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
EP2477973B1 (en) 2009-09-16 2014-08-27 Ranbaxy Laboratories Limited Process for the preparation of a crystalline form of lenalidomide
TWI475014B (zh) 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN101696205B (zh) 2009-11-02 2011-10-19 严荣 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of form b of lenalidomide
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
WO2011069608A1 (en) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
CN101817813B (zh) 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体Ⅳ及其药用组合物
US8877932B2 (en) 2010-03-08 2014-11-04 Natco Pharma Limited Anhydrous lenalidomide form-I
CN101791288B (zh) 2010-04-07 2011-12-28 严荣 一种稳定的来那度胺口服固体制剂
CN102453021A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 来那度胺的新晶型及其制备方法

Also Published As

Publication number Publication date
DK3045175T3 (en) 2019-03-04
US20120029020A1 (en) 2012-02-02
CA2688695A1 (en) 2005-03-17
EP3045175B1 (en) 2018-11-07
MXPA06001994A (es) 2006-05-31
CN102584788A (zh) 2012-07-18
ES2376879T3 (es) 2012-03-20
CA2688708A1 (en) 2005-03-17
ME01571B (me) 2014-09-20
CN102675281A (zh) 2012-09-19
MX342025B (es) 2016-09-12
US20160009684A1 (en) 2016-01-14
IL174067D0 (en) 2006-08-01
EP3045175B8 (en) 2018-12-19
CA2537092A1 (en) 2005-03-17
CN104059052A (zh) 2014-09-24
JP6200977B2 (ja) 2017-09-20
DK1667682T3 (da) 2011-12-12
IL225791D0 (en) 2013-06-27
CN1871003A (zh) 2006-11-29
DK2426118T3 (da) 2013-03-25
EP3459544A1 (en) 2019-03-27
HK1167646A1 (xx) 2013-10-18
JP2016074734A (ja) 2016-05-12
HUE041265T2 (hu) 2019-05-28
CA2741575A1 (en) 2005-03-17
NZ546054A (en) 2009-12-24
NO20061528L (no) 2006-06-02
OA13250A (en) 2007-01-31
US9353080B2 (en) 2016-05-31
CA2688709C (en) 2011-08-09
CN101838261B (zh) 2013-07-10
EP3042659B8 (en) 2018-12-19
ME01572B (me) 2014-09-20
PT1667682E (pt) 2012-01-19
US7855217B2 (en) 2010-12-21
HK1148974A1 (xx) 2013-02-08
KR100979869B1 (ko) 2010-09-02
US20180072700A1 (en) 2018-03-15
US20170121304A1 (en) 2017-05-04
RS20120339A1 (xx) 2013-04-30
AT531369T (de) 2011-11-15
BRPI0414084A (pt) 2006-10-24
WO2005023192A3 (en) 2005-09-29
ZA200601858B (en) 2007-07-25
EP2425836A1 (en) 2012-03-07
CY1112017T1 (xx) 2015-11-04
US20170121305A1 (en) 2017-05-04
US20170121303A1 (en) 2017-05-04
US8431598B2 (en) 2013-04-30
EP3042659B1 (en) 2018-11-07
RS20120340A1 (xx) 2013-04-30
US20120029019A1 (en) 2012-02-02
EP3045176A1 (en) 2016-07-20
KR101005991B1 (ko) 2011-01-05
CN101863878A (zh) 2010-10-20
JP5309104B2 (ja) 2013-10-09
US8193219B2 (en) 2012-06-05
AU2009200257B2 (en) 2012-02-02
CN102060843A (zh) 2011-05-18
NO20160131A1 (no) 2016-01-28
IS8340A (is) 2006-03-07
NO336898B1 (no) 2015-11-23
JP2011137024A (ja) 2011-07-14
CA2687924C (en) 2011-08-09
HK1092388A1 (xx) 2012-11-16
CR8291A (es) 2007-09-17
MA28084A1 (fr) 2006-08-01
JP4733037B2 (ja) 2011-07-27
CA2688695C (en) 2011-08-09
CA2688709A1 (en) 2005-03-17
HUE042071T2 (hu) 2019-06-28
IL225792D0 (en) 2013-06-27
EP3045175A1 (en) 2016-07-20
PT2426118E (pt) 2013-04-04
KR20090086647A (ko) 2009-08-13
US8143286B2 (en) 2012-03-27
PE02842006A1 (es) 2006-04-13
EP1667682A4 (en) 2009-05-06
IL238911D0 (en) 2015-06-30
AR102756A2 (es) 2017-03-22
ECSP066467A (es) 2006-09-18
ME01530B (me) 2011-10-10
PL3045176T3 (pl) 2019-04-30
JP5925418B2 (ja) 2016-05-25
EA009922B1 (ru) 2008-04-28
NO341039B1 (no) 2017-08-14
IL207458D0 (en) 2010-12-30
PL3045175T3 (pl) 2019-04-30
CN101838261A (zh) 2010-09-22
CA2688708C (en) 2011-08-09
CA2741575C (en) 2013-07-16
US20110015228A1 (en) 2011-01-20
NO20161012A1 (no) 2016-06-15
CA2741412C (en) 2013-07-16
NO341035B1 (no) 2017-08-07
EP2426118A1 (en) 2012-03-07
US20120046316A1 (en) 2012-02-23
CA2537092C (en) 2011-08-09
PL3042659T3 (pl) 2019-04-30
CA2741412A1 (en) 2005-03-17
CR10967A (es) 2009-12-10
DK3042659T3 (en) 2019-02-25
EP1667682A2 (en) 2006-06-14
US20090187023A1 (en) 2009-07-23
MX346260B (es) 2017-03-13
EP3045176B1 (en) 2018-11-07
CA2688694C (en) 2011-08-09
HK1202531A1 (en) 2015-10-02
US20090149499A1 (en) 2009-06-11
DK3045176T3 (en) 2019-02-25
IL207458A (en) 2015-08-31
US20090176832A1 (en) 2009-07-09
US20110288127A1 (en) 2011-11-24
ES2718925T3 (es) 2019-07-05
EP3045176B8 (en) 2018-12-12
SI2426118T1 (sl) 2013-06-28
SI1667682T1 (sl) 2011-12-30
CN1871003B (zh) 2012-03-14
US20190218201A1 (en) 2019-07-18
AP200603558A0 (en) 2006-04-30
UA83504C2 (xx) 2008-07-25
CA2688694A1 (en) 2005-03-17
EP2426118B1 (en) 2013-01-23
JP2013209407A (ja) 2013-10-10
ES2718927T3 (es) 2019-07-05
KR20080063862A (ko) 2008-07-07
NO337446B1 (no) 2016-04-11
EP3042659A1 (en) 2016-07-13
US7465800B2 (en) 2008-12-16
US7977357B2 (en) 2011-07-12
CN102060843B (zh) 2013-08-14
US9371309B2 (en) 2016-06-21
JP2007504248A (ja) 2007-03-01
EA200600535A1 (ru) 2006-08-25
AU2004270211A1 (en) 2005-03-17
CN101863878B (zh) 2012-07-18
MX346261B (es) 2017-03-13
US20090062343A1 (en) 2009-03-05
MX342071B (es) 2016-09-13
CA2687927C (en) 2012-05-29
CN102675281B (zh) 2016-01-20
AP2324A (en) 2011-11-21
ES2402808T3 (es) 2013-05-09
JP2014094957A (ja) 2014-05-22
KR20060087543A (ko) 2006-08-02
HUE041282T2 (hu) 2019-05-28
US20120022106A1 (en) 2012-01-26
NO20150253L (no) 2006-06-02
US20090149500A1 (en) 2009-06-11
HK1148274A1 (xx) 2013-11-29
US9365538B2 (en) 2016-06-14
AU2004270211B2 (en) 2008-10-23
HRP20110836T1 (xx) 2011-12-31
JP2011006470A (ja) 2011-01-13
MX346372B (es) 2017-03-16
US8058443B2 (en) 2011-11-15
ES2718926T3 (es) 2019-07-05
US8822499B2 (en) 2014-09-02
CA2687924A1 (en) 2005-03-17
IL174067A (en) 2015-07-30
RS53104B (xx) 2014-06-30
CA2687927A1 (en) 2005-03-17
WO2005023192A2 (en) 2005-03-17
US20050096351A1 (en) 2005-05-05
EP1667682B1 (en) 2011-11-02
RS20060158A (xx) 2008-08-07
AR047994A1 (es) 2006-03-15
AU2009200257A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
JP2004041779A5 (xx)
JP2004040822A5 (xx)
JP2004007842A5 (xx)
JP2004004971A5 (xx)
JP2004039231A5 (xx)
JP2004104127A5 (xx)
JP2004068159A5 (xx)
JP2004078212A5 (xx)
JP2004104782A5 (xx)
JP2004051483A5 (xx)
JP2004085585A5 (xx)
JP2004082730A5 (xx)
JP2004003384A5 (xx)
JP2004048067A5 (xx)
JP2004041804A5 (xx)
JP2004072106A5 (xx)
JP2004072101A5 (xx)
JP2004091491A5 (xx)
JP2004062912A5 (xx)
JP2004010618A5 (xx)
JP2004089196A5 (xx)
JP2004108582A5 (xx)
JP2004051482A5 (xx)
JP2004062202A5 (xx)
JP2004065264A5 (xx)

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE CHINESE NAME OF THE INVENTOR FROM

Effective date: 20140415

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170903